Winstgevend schreef op 28 juni 2019 13:25:
Pharming moved the timing of the start of the clinical studies of new delivery methods
for Ruconest (intramuscular, subcutaneous, intradermal) from H1/19 into H1/20.
The delay relates to constraints on the supply of Ruconest required for the clinical studies.
Currently all available production capacity is required for patients.
Pharming’s management expects clearance for the start of production at
two new Ruconest production facilities from the European and U.S. authorities in Q3/19
Dit onderbouwd de enorme en overstijgende vraag naar Ruconest voor de komende jaren.